2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
E. David Crawford, MD, professor of Radiation Oncology, University of Colorado School of Medicine, discusses challenges facing PSA testing for patients with prostate cancer.
E. David Crawford, MD, professor of Radiation Oncology, University of Colorado School of Medicine, discusses challenges facing PSA testing for patients with prostate cancer.
In the future of prostate cancer, it is important to find men who will respond to treatment and not just overtreat them, explains Crawford. Appropriate PSA testing and analysis can help reduce overtreatment.
Crawford simplifies PSA testing by stating that a PSA less than 1.5 is a cutoff point where the patient can return for testing in 5 years, if the PSA is greater than 1.5 then further testing is required.
Related Content: